SPARC enters pact with UCSF and Tiller Therapeutics for early stage oncology asset

Sun Pharma Advanced Research Company (SPARC) partners with Tiller Therapeutics. SPARC licenses its rights to a promising cancer treatment. The deal involves a pre-clinical oncology asset. SPARC gets a 55% equity stake in Tiller. This stake vests in two parts. The deal may lead to new treatments for solid tumors. SPARC shares saw a slight dip on Tuesday.